Skip to main content
36 search results for:

Stereotactic body radiotherapy 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 26-02-2019 | Non-small-cell lung cancer | News | Article

    Stereotactic ablative body radiotherapy benefits shown in early NSCLC

    Patients with inoperable peripherally located stage 1 non-small-cell lung cancer achieve better local control and overall survival with stereotactic ablative body radiotherapy than with standard radiotherapy, phase III study data show.

  2. 06-10-2023 | Prostate cancer | News | Article

    Add-on SBRT improves outcomes of men with oligometastatic CRPC

    Patients with oligometastatic castration-resistant prostate cancer benefit from the addition of stereotactic body radiotherapy to first-line abiraterone acetate plus prednisone.

  3. 18-08-2023 | Non-small-cell lung cancer | News | Article

    Combining SABR with immunotherapy prolongs NSCLC event-free survival

    Patients with treatment-naïve, early-stage or isolated parenchymal recurrent NSCLC benefit from the addition of immunotherapy to stereotactic ablative radiotherapy, indicate phase 2 results.

  4. 30-11-2022 | Renal cell carcinoma | News | Article

    Long-term findings support SABR for localized RCC

    Stereotactic ablative body radiotherapy has high local efficacy and minimal impact on renal function in the long term among people with localized renal cell carcinoma, say researchers who conducted an individual patient data meta-analysis of the IROCK database.

  5. 04-10-2022 | Prostate cancer | News | Article

    PACE-B suggests prostate ultra-hypofractionated SBRT is ‘safe’

    Ultra-hypofractionated stereotactic body radiotherapy has a low rate of side effects, similar to a standard course of conventionally or moderately hypofractionated radiotherapy for low- or intermediate-risk prostate cancer, indicate 2-year toxicity findings from the phase 3 PACE-B trial.

  6. 07-04-2022 | Lung cancer | News | Article

    Research calls for radiation oncologist involvement in lung nodule management

    US researchers say that almost a quarter of people with screen-detected pulmonary nodules receive stereotactic body radiation therapy, highlighting the “critical role” radiation oncologists play in the management of these patients.

  7. 07-09-2021 | Oligometastases | News | Article

    Single-fraction SABR may be preferred for lung oligometastases

    Stereotactic ablative body radiotherapy offers similar outcomes, in terms of toxicity and efficacy, whether it is given as a single fraction or in multiple fractions to patients with up to three lung oligometastases, SAFRON II trial data show.

  8. 02-11-2021 | Renal cell carcinoma | News | Article

    Radiotherapy without systemic therapy feasible for oligometastatic RCC

    Definitive radiotherapy without systemic therapy may be a feasible strategy for the treatment of oligometastatic renal cell carcinoma, phase 2 study findings indicate.

  9. 25-06-2021 | Non-small-cell lung cancer | News | Article

    Adding SBRT to neoadjuvant durvalumab shows promise in early NSCLC

    The addition of stereotactic body radiotherapy to neoadjuvant durvalumab significantly improves the major pathologic response rate in patients with early-stage non-small-cell lung cancer, phase 2 trial data suggest.

  10. 23-03-2021 | Prostate cancer | News | Article

    PROSINT: Single dose of radiation ‘feasible’ for organ-confined prostate cancer

    One ultra-high dose of radiation may offer similar benefits and risks to those of an extreme hypofractionated stereotactic body radiotherapy regimen for men with organ-confined prostate cancer, indicate the results of a phase 2 proof-of-concept trial.

  11. play
    14-02-2021 | ASCO GU 2021 | Conference coverage | Video

    Pembrolizumab, SABR develop a RAPPORT for oligometastatic RCC

    Shankar Siva provides an overview of the RAPPORT study of pembrolizumab plus stereotactic ablative body radiotherapy for the treatment of renal cell carcinoma with oligometastases.

  12. 14-01-2021 | Oligometastases | News | Article

    Real-world data support efficacy of SABR for extracranial oligometastases

    The beneficial survival outcomes and low toxicity associated with stereotactic ablative body radiotherapy in patients with extracranial oligometastases persist in the real-world setting.

  13. 14-01-2021 | Oligometastases | Highlight | Teaser
    medwireNews top story

    Real-world data support efficacy of SABR for extracranial oligometastases

    The beneficial survival outcomes and low toxicity associated with stereotactic ablative body radiotherapy in patients with extracranial oligometastases persist in the real-world setting.

  14. 22-12-2020 | Oligometastases | News | Article

    SBRT favorable for extracranial oligometastases

    Patients with extracranial oligometastases derive a long-term survival benefit from stereotactic body radiotherapy, research suggests.

  15. 26-11-2020 | Oligometastases | News | Article

    Oligometastatic cancer outcomes acceptable with SABR

    Stereotactic ablative radiotherapy is associated with “clinically acceptable” rates of toxicity, local control, progression-free survival, and overall survival in people with oligometastatic cancer, meta-analysis data suggest.

  16. 14-10-2020 | Immunotherapy | News | Article

    Prior immune-related AEs linked to high radiation pneumonitis risk

    Patients with prior immune checkpoint inhibitor-induced immune-related adverse events have a very high risk for developing radiation pneumonitis from thoracic radiotherapy, US researchers report.

  17. 18-02-2020 | ASCO GU 2020 | News | Article

    Further investigation of combined immunotherapy, SBRT may be warranted for mRCC

    Findings from two phase 2 trials suggest that combining immune checkpoint inhibition with stereotactic body radiotherapy is feasible in patients with metastatic renal cell carcinoma. This independent news story was supported by an educational grant from Pfizer and Merck KGaA

  18. play
    15-02-2020 | ASCO GU 2020 | Conference coverage | Video

    Researcher comment: The RADVAX RCC study

    Hans Hammers discusses the RADVAX RCC trial combining dual checkpoint blockade and stereotactic body radiotherapy for the treatment of metastatic renal cell carcinoma, and also comments on the similar NIVES study (2:16). Read the accompanying news story This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

  19. NIVES trial

    The NIVES study is investigating the efficacy of concomitant nivolumab and stereotactic body radiotherapy in the metastatic RCC setting.

  20. 08-10-2019 | Prostate cancer | News | Article

    Ultra-hypofractionated SBRT has low acute toxicity in localized prostate cancer

    Ultra-hypofractionated stereotactic body radiotherapy does not increase the risk for acute toxicity over standard of care radiotherapy in men with localized prostate cancer, according to a phase III trial.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.